An Expert View from Dr Elena Wolff-Holz, global head of clinical development at Biocon Biologics, the biosimilar subsidiary ...

The formulation comparison between a biosimilar and a branded biologic. The cost, availability, and supply chain benefits of ...

CVS Caremark, Express Scripts and Optum Rx — the three largest pharmacy benefit managers in the U.S. — each excluded more ...

More ‘biosimilar’ medicines should be brought to market in the EU because of a regulatory policy shift on the need to carry ...

The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, ...

Biosimilars offer affordable medical treatments, but regulatory guidelines need updating to ensure safety, efficacy, and ...

India needs to update its biosimilar regulations to ensure safe, effective, and affordable medicines, balancing quality and cost for better patient care.